Application of the LDL-Density-Radius Theory: The Aortic Valve

  • Nalini M. Rajamannan
  • Francesco Antonini-Canterin
  • Kristian Wachtal
Chapter

Abstract

With the decline incidence of rheumatic carditis, calcific aortic valve disease (CAVD) [1] has become the most common indication for surgical valve replacement in the United States and in Europe [2]. Numerous epidemiologic studies identified risk factors for CAVD, which are similar to those of vascular atherosclerosis, including smoking, male gender, body mass index, hypertension, elevated lipid and inflammatory markers, metabolic syndrome and renal failure [3–19]. For years, this disease process was thought to be due to a degenerative phenomenon by which calcium attached to the surface of the aortic valve leaflet. Understanding calcification, as the critical end-stage process which causes progression to severe stenosis and leads to poor outcomes [20], is becoming important in the results of the randomized trials for treating aortic stenosis with medical therapy. To date, these trials, including SALTIRE, Simvastatin Ezetimibe in Aortic Stenosis (SEAS), Aortic Stenosis Progression Observation: Measuring the Effects of Rosuvastatin (ASTRONOMER), have all been negative [21–23]. Over the past decade, data from several studies have confirmed that all of these traditional risk factors, including metabolic syndrome [13] and renal failure [14], which are important in the development of vascular atherosclerosis, and are also implicated in the development of CAVD [3–19]. These findings provide the foundation to study targeted strategies for medical therapy, including for example, medications for hyperlipidemia, hypertension and diabetes. There are a growing number of experimental in vivo models of calcific AS, which demonstrate primarily that lipids [24–30], diabetes [30] and renal failure [31] are important in the development of this disease. There is also increasing evidence that these cells undergo specific differentiation steps towards the development of this bone phenotype as shown in in vitro studies [32–34]. In addition, there are a growing number of retrospective [35–38] and the large-scale prospective clinical trials [21–23] testing the hypothesis that atherosclerotic CAVD may be targeted with medical therapy. The only clinical trial to date Rosuvastatin Affecting Aortic Valve Endothelium to Slow the Progression of Aortic Stenosis trial (RAAVE) was a positive study testing the hypothesis that treating elevated LDL as compared to normal LDL patients slows progression of CAVD [21]. The retrospective studies published to date are shown in Fig. 17.2 [35–38].

Keywords

Placebo Cholesterol Sugar Europe Stratification 

References

  1. 1.
    Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124:1783–91.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis. 1984;37:407–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol. 1985;55:744–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol. 1987;59:998–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors–a causal relationship? A clinical morphologic study. Clin Cardiol. 1991;14:995–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkila J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 1994;15:865–70.PubMedGoogle Scholar
  9. 9.
    Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart. 1997;78:472–4.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Chui MC, Newby DE, Panarelli M, Bloomfield P, Boon NA. Association between calcific aortic stenosis and hypercholesterolemia: Is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol. 2001;24:52–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart. 1997;78:475–9.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Chan KL, Ghani M, Woodend K, Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol. 2001;88:690–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP, Arsenault M, Couet J, Pibarot P.Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol. 2006;47:2229–36.PubMedCrossRefGoogle Scholar
  14. 14.
    Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101:2497–502.PubMedCrossRefGoogle Scholar
  15. 15.
    Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy CM. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol. 2003;91:97–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol. 1997;29:630–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–7 [comment].PubMedCrossRefGoogle Scholar
  18. 18.
    Faggiano P, Antonini-Canterin F, Baldessin F, Lorusso R, D’Aloia A, Cas LD. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound. 2006;4:27.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104:1927–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352(23):2389–97.Google Scholar
  22. 22.
    Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (astronomer) trial. Circulation. 2010;121:306–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105:2260–5.CrossRefGoogle Scholar
  25. 25.
    Rajamannan NM, Sangiorgi G, Springett M, Arnold K, Mohacsi T, Spagnoli LG, Edwards WD, Tajik AJ, Schwartz RS. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis. 2001;10:371–4.PubMedGoogle Scholar
  26. 26.
    Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 2003;41:1211–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114:2065–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007;115:377–86.PubMedCrossRefGoogle Scholar
  29. 29.
    Drolet MC, Roussel E, Deshaies Y, Couet J, Arsenault M. A high fat/high carbohydrate diet induces aortic valve disease in c57bl/6j mice. J Am Coll Cardiol. 2006;47:850–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine wnt signals. J Clin Invest. 2005;115:1210–20.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101(21):2497–502.Google Scholar
  32. 32.
    Blevins TL, Peterson SB, Lee EL, Bailey AM, Frederick JD, Huynh TN, Gupta V, Grande-Allen KJ. Mitral valvular interstitial cells demonstrate regional, adhesional, and synthetic heterogeneity. Cells Tissues Organs. 2008;187:113–22.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol. 2007;171:1407–18.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Yip CY, Chen JH, Zhao R, Simmons CA. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler Thromb Vasc Biol. 2009;29:936–42.PubMedCrossRefGoogle Scholar
  35. 35.
    Antonini-Canterin F, Popescu BA, Huang G, Korcova-Miertusova R, Rivaben D, Faggiano P, Pavan D, Piazza R, Bolis A, Ciavattone A, Ruggiero A, Nicolosi GL. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J. 2005;6:119–24.PubMedGoogle Scholar
  36. 36.
    Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723–30 [comment].PubMedCrossRefGoogle Scholar
  37. 37.
    Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O’Brien KD. Hmg coa reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359:1125–6 [comment].PubMedCrossRefGoogle Scholar
  38. 38.
    Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49(5):554–61.Google Scholar
  40. 40.
    Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–97.PubMedCrossRefGoogle Scholar
  41. 41.
    Newby DE, Cowell SJ, Boon NA. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart. 2006;92:729–34.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–80.Google Scholar
  43. 43.
    Bernoulii D. Hydrodynamica Sive De Viribus et Motibus Fluidorum Commentarrii. Strasbourg: Argentoratum, St 31. 1738.Google Scholar
  44. 44.
    Rajamannan NM. Mechanisms of aortic valve calcification: the ldl-density-radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol. 2010;298:H5–15.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Descartes, La Geometrie appendix: Discours de la Methode pour bien condiuire sa raison, et chercher la verite dans les sciences, 1637.Google Scholar
  46. 46.
    Rajamannan NM, Best P, Antonini-Canterin F, Moura LM, Saltire-raave subanalysis: a role for statins in aortic valve disease. J Am Coll Cardiol. 2011;57(14):E1317.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Nalini M. Rajamannan
    • 1
  • Francesco Antonini-Canterin
    • 2
  • Kristian Wachtal
    • 3
  1. 1.Division of Biochemistry and Molecular BiologyMayo ClinicRochesterUSA
  2. 2.Preventive and Rehabilitative CardiologyCardiologia ARC, Azienda Ospedaliera “S. Maria degli Angeli”PordenoneItaly
  3. 3.Department of Medicine, Glostrup HospitalUniversity of CopenhagenGlostrupDenmark

Personalised recommendations